Anko's anti-tumor innovation drugs were approved by clinical trials

Home > Health

Anko's anti-tumor innovation drugs were approved by clinical trials

2021-11-27 00:07:07 43 ℃

Xinjing News (Reporter Zhang Zhaihui) November 26th, Anke Biological Release Announcement Source subclonal antibody tumor immunotherapy drugs.

4-1BB is encoded by a tumor necrosis factor receptor superfamily member 9 (TNFRSF9) gene, is a common stimuli receptor expressed in a variety of cells in the immune system, including activated CD4 + and CD8 + T cells, naturally killing T cells ( NKT) and natural kill cells (NKs), differentiated tits, monocytes, eosinophils, neutrophils, dendritic cells (DCs) and stimulating hypertrophytes, and Treg cells. 4-1BB and ligand 4-1bbl binding to increase T cell survival, proliferation, and cytokine production, thereby activating the body's immune system, reaching the development of tumors, promoting tumor removal anti-tumor effects.

Pre-clinical studies have shown that ZG033 injection can rely on FcγR to promote T cell, NK cell proliferation, activation, and cytokine production, exhibit good tumor inhibitory effect in 4-1 bb humanized mouse stock model, in the crab monkey Good safety also exhibits good safety in the toxicological experiment. Up to now, the target-related monoclonal or double-resistant is still listed in the clinical trial stage, and there is no relevant target drugs at home and abroad.